Agios Pharmaceuticals reported second quarter 2026 results with worldwide net revenues of $44.7 million, driven by a strong U.S. commercial launch of AQVESME in thalassemia and ex-U.S. sales of PYRUKYND. The company recorded a net loss of $100.7 million, an improvement from the $112.0 million loss in the prior year period. R&D expenses increased to $100.8 million due to a $25.0 million upfront payment for the cevidoplenib license agreement with Oscotec. The FDA granted Priority Review for the supplemental New Drug Application of mitapivat for sickle cell disease, setting a PDUFA goal date of November 1, 2026. Agios holds $964.8 million in cash and marketable securities as of June 30, 2026. The company operates in the biopharmaceutical industry, developing innovative medicines for rare diseases.

At the 2026 Annual Meeting of Stockholders held on June 18, 2026, Agios Pharmaceuticals, Inc. stockholders approved an amendment to the 2023 Stock Incentive Plan to increase the number of shares available for issuance under the plan by 2,000,000 shares. Additionally, stockholders elected Class I directors Rahul Ballal, Ph.D., Brian Goff, and Cynthia Smith to three-the-year terms. Agios Pharmaceuticals, Inc. is a biotechnology company that develops and commercializes therapeutic products for patients with metabolic and hematologic disorders.